Meta-analysis of RCTs to identify mHSPC patient groups with optimal benefit of addition of docetaxel to androgen deprivation therapy

Addition of docetaxel to androgen deprivation therapy (ADT) improves survival in patients with metastatic, hormone-sensitive prostate cancer (mHSPC), but uncertainty remains about who benefits most. Meta-analysis of individual participant data of three randomized trials (n=2261) found that among these patients addition of docetaxel to ADT is best suited to patients with poorer prognosis based on a high volume of disease and potentially the bulkiness of the primary tumor. The authors conclude that these results will better characterize patients most and, importantly, least likely to gain benefit from docetaxel.